1. Academic Validation
  2. Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity

Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity

  • ACS Med Chem Lett. 2012 Nov 12;4(1):46-51. doi: 10.1021/ml300262e.
Dean G Brown 1 Peter R Bernstein 1 Ye Wu 1 Rebecca A Urbanek 1 Christopher W Becker 1 Scott R Throner 1 Bruce T Dembofsky 1 Gary B Steelman 1 Lois A Lazor 1 Clay W Scott 1 Michael W Wood 1 Steven S Wesolowski 1 David A Nugiel 1 Stephanie Koch 1 Jian Yu 1 Donald E Pivonka 1 Shuang Li 1 Carol Thompson 1 Anna Zacco 1 Charles S Elmore 1 Patricia Schroeder 1 JianWei Liu 1 Christopher A Hurley 2 Stuart Ward 2 Hazel J Hunt 2 Karen Williams 2 Joseph McLaughlin 1 Valerie Hoesch 1 Simon Sydserff 1 Donna Maier 1 David Aharony 1
Affiliations

Affiliations

  • 1 CNS Discovery Research, AstraZeneca Pharmaceuticals , 1800 Concord Pike, Wilmington, Delaware 19850-5437, United States.
  • 2 Argenta , 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom.
Abstract

Herein, we describe the discovery of inhibitors of norepinephrine (NET) and dopamine (DAT) transporters with reduced activity relative to serotonin transporters (SERT). Two compounds, 8b and 21a, along with nomifensine were tested in a rodent receptor occupancy study and demonstrated dose-dependent displacement of radiolabeled NET and DAT ligands. These compounds were efficacious in a rat forced swim assay (model of depression) and also had activity in rat spontaneous locomotion assay.

Keywords

antidepressant; dopamine; norepinephrine; uptake inhibitors.

Figures